← All indications
Hematologic Diseases
Disorders of the blood and blood forming tissues.
Subtype terms (19)
More specific conditions that are subtypes of Hematologic Diseases in the MeSH hierarchy.
- Anemia
326 drugs (199 approved, 127 experimental)
- Blood Coagulation Disorders
34 drugs (25 approved, 9 experimental)
- Blood Platelet Disorders
52 drugs (36 approved, 16 experimental)
- Blood Protein Disorders
16 drugs (12 approved, 4 experimental)
- Bone Marrow Diseases
59 drugs (44 approved, 15 experimental)
- Cytopenia
- Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)
- Hematologic Neoplasms
339 drugs (162 approved, 177 experimental)
- Hemoglobinopathies
42 drugs (27 approved, 15 experimental)
- Hemorrhagic Disorders
15 drugs (6 approved, 9 experimental)
- Leukemia
598 drugs (276 approved, 322 experimental)
- Leukocyte Disorders
4 drugs (3 approved, 1 experimental)
- Methemoglobinemia
6 drugs (5 approved, 1 experimental)
- Polycythemia
13 drugs (11 approved, 2 experimental)
- Pregnancy Complications, Hematologic
2 drugs approved
- Preleukemia
11 drugs (7 approved, 4 experimental)
- Sulfhemoglobinemia
- Thrombophilia
12 drugs (8 approved, 4 experimental)
- Transfusion Reaction
11 drugs (7 approved, 4 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (9)
Phase 3 trials (32)
- decitabine
- antilymphocyte serum
- acetylcysteine
- autologous blood
- procaine benzylpenicillin
- busulfan
- lenalidomide
- doxorubicin
- fluorouracil
- imatinib
- hydroxyurea
- leucovorin
- megakaryocytic progenitor cells
- human factor ix complex (prothrombin complex concentrate)
- oprelvekin
- radotinib
- red blood cells
- thrombopoietin
- cyclophosphamide
- stem cells
- alemtuzumab
- whole blood
- nandrolone phenpropionate
- autologous mesenchymal stem cells
- fludarabine
- allogeneic blood cells
- bivalirudin
- thiotepa
- sargramostim
- riboflavin
- +2 more
Phase 2 trials (56)
- allopurinol
- 23-valent pneumococcal polysaccharide vaccine
- urea
- benralizumab
- brentuximab vedotin
- pyridoxal isonicotinoyl hydrazone
- diphenhydramine
- deferoxamine
- micafungin
- tacrolimus
- hemopoietic stem cell
- fibrinogen (human)
- levamisole
- allogeneic stem cells
- peripheral blood lymphocytes
- acetaminophen
- carmustine
- allogeneic hematopoietic stem cells
- ruxolitinib
- Isatuximab
- talmapimod
- sirolimus
- cyclosporine
- mycophenolate
- sonidegib
- everolimus
- pacritinib
- Anti-thymocyte Globulin (Rabbit)
- itraconazole
- bortezomib
- +26 more
Phase 1 trials (26)
- ferric derisomaltose
- fostemsavir
- aldesleukin
- Sovleplenib
- dibotermin alpha
- mbg453
- vincristine
- orh-2014
- pul-042
- mannose binding lectin
- arsenic trioxide
- tefinostat
- zoledronic acid
- allogeneic adipose derived mesenchymal stem cell
- mesna
- daratumumab
- spartalizumab
- allogeneic gamma-delta t cells
- t-allo10
- tcrαβ+/cd19+ depleted allogeneic hematopoietic stem cell
- maat033
- rd13-01
- anv419
- gsk4172239d
- oricar-017
- rlyb116
Other trials (24)
- thalidomide
- albendazole
- desmopressin
- bismuth
- ginger
- hetrombopag olamine
- bone marrow derived mesenchymal stem cells
- deferiprone
- levetiracetam
- lavender
- praziquantel
- acetylsalicylic acid
- testosterone
- fluconazole
- sildenafil
- tranexamic acid
- clopidogrel
- potato starch
- voriconazole
- lv-nyeso tcr /sr39tk pbsc
- rv-nyeso tcr pbmc
- arginine
- bd211
- sa55
Organizations
Organization Involved with Phase 4 Indications (10)
- CSL Behring
- Bayer
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Medical College of Wisconsin
- Jiao Tong University
- Mountain States Regional Hemophilia Center, Aurora, Columbia
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- Jackson Laboratory
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (62)
- Celgene
- Hamad Medical Corporation
- Il-Yang Pharm. Co., Ltd.
- National Institutes of Health (NIH)
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Ain Shams University
- Baylor University
- Drexel University
- Duke University
- Emory University
- Guangzhou Medical University
- Hoosier Cancer Research Network
- Howard University
- Johns Hopkins University
- Nagoya University
- Semmelweis University
- Rutgers University
- Thomas Jefferson University
- University of Kansas
- University of Maryland
- University of Medicine and Dentistry of New Jersey
- University of Miami
- University of Oregon
- Wayne State University
- Columbia University
- East Carolina University
- Peking University
- Soochow University
- +32 more
Organization Involved with Phase 2 Indications (43)
- Biomarin
- Jazz Pharmaceuticals
- Seattle Genetics
- Scios
- Amgen
- Vertex
- AstraZeneca
- Merck
- Novartis
- Kiadis Pharma
- Spark Therapeutics
- University of Pennsylvania
- Case Western Reserve University
- Harvard University
- University of Washington
- Institut Paoli-Calmettes
- New York Medical College
- Northwestern University
- Stanford University
- University of Michigan
- University of Toronto
- Wuhan University
- Yonsei University
- Fudan University
- Xiamen University
- University of California, San Francisco
- University of Chicago
- Food and Drug Administration
- University of Freiburg
- Texas Transplant Institute
- +13 more
Organization Involved with Phase 1 Indications (17)
- Enzon
- Cellphire, Inc.
- Chroma Therapeutics
- MaaT Pharma
- Orsenix LLC
- Pharmacosmos
- Agios Pharmaceuticals, Inc.
- Pulmotect, Inc.
- University of Rochester
- Free University of Amsterdam
- AXIS Clinicals Limited
- ZNA Stuivenberg
- Erasmus University Rotterdam
- Department of Health and Human Services
- State of Texas
- IUCT
- Acrotech Biopharma LLC
Organization Involved with Other Experimental Indications (19)
- Abbott
- National Institute for Medical Research, Tanzania
- Catholic University of Health and Allied Sciences
- Cornell University
- Makerere University
- University of Florida
- University of Nebraska
- University of Oklahoma
- University of Bern
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
- University of British Columbia
- University of California, San Diego
- University of Cambridge
- University of Copenhagen
- King Abdullah Medical City
- Blood and Marrow Transplant Clinical Trials Network
- Blue Cross Blue Shield
- Centers for Disease Control and Prevention (CDC)
- King Abdul-Aziz University